A Phase 1 interventional study of Abrocitinib tablet and Abrocitinib Suspension F1 in Healthy Volunteers, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-14.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.
Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 18th largest by enrollment, is the only one that started in 2021, is one of 3 in phase 1, and was the 12th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
Pfizer · Sites in United States, China, Hungary and 4 more countries
Ages 2–11
Pfizer
Ages 2–5
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 150 across the 20 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 5 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
58 studies in Dermatitis, Atopic by Pfizer: 11 open now, 13 under way, 4 of them phase 3. Of 43 finished, 34 (79%) have results posted.
Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 43rd largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2021, is one of 13 in phase 1, and was the 35th registered.
Pfizer’s Dermatitis, Atopic studies by the year they started, since 2009.
1 of the studies testing abrocitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07848074Fondazione Policlinico Universitario Agostino Gemelli IRCCSAbrocitinib Dose Tapering in Patients With Atopic Dermatitis | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing abrocitinib in Dermatitis, Atopic, from their registry updates:
Among Pfizer’s 58 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This study consists of 2 parts: Part A is to estimate the relative bioavailability of a single 200 mg dose of abrocitinib oral suspension (Test formulation) compared to the commercial abrocitinib tablet (200 mg) (Reference formulation). The effect of an acid-reducing agent on the pharmacokinetics of abrocitinib and its metabolites will also be evaluated by administering abrocitinib 200 mg commercial tablet with or without famotidine 40 mg, as an acid-reducing agent. Part B is to assess the taste and palatability of six different abrocitinib oral suspension formulations. Additionally, the safety and tolerability of abrocitinib tablet (in Part A) and abrocitinib oral suspension formulations (in Part B) will be assessed when given with or without famotidine 40 mg once daily.
This is a Phase 1 randomized study in healthy participants to estimate the relative bioavailability of abrocitinib oral suspension (Test formulation) compared to commercial abrocitinib tablet (Reference formulation) under fasted condition. The effect of an acid-reducing agent on the pharmacokinetics of the commercial tablet formulation will be evaluated by administering abrocitinib 200 mg commercial tablet with famotidine 40 mg, as an acid-reducing agent. Assessment of taste and palatability of six different abrocitinib suspension formulations will also be performed. This study consists of 2 parts, as listed below:
Part A
Part A of the study will be an open label, randomized, single dose, crossover, 3-treatment, 6 sequence, 3-period design in healthy male and/or female adult participants (18-55 years). Healthy participants will be screened within 28 days prior to the first administration of the study intervention to confirm that they meet the participant selection criteria for the study. Eligible participants will be admitted to the CRU on Day -1 and will be confined in the CRU until discharge, on Day 2 of Period 9 in Part B, after completing both Parts A and B of the study. In Part A, participants will be randomized to receive one of the following: a single 200 mg dose of abrocitinib commercial tablet (Treatment A), a single 200 mg dose of abrocitinib oral suspension formulation 1 (Treatment B), or famotidine (40 mg) administered 120 minutes before a single 200 mg dose of abrocitinib commercial tablet (Treatment C). All participants will be fasting for at least 10 hours before taking abrocitinib.
Part B
Part B will be a single-blind, randomized, 6-period, crossover study in healthy male and/or female adult participants (18-55 years). For any new healthy participants joining Part B only, screening will be performed within 28 days prior to the first administration of the study intervention to confirm that they meet the participant selection criteria for the study. New participants enrolled in Part B only will be admitted to the CRU on Day -1 and will be confined in the CRU until discharge, which is Day 2 of Period 9. On Day 1 of each treatment period under fasted conditions, participants will receive a famotidine tablet (40 mg with 240 mL of room temperature water) administered 120 minutes before a single 200 mg dose of abrocitinib oral suspensions (Formulations 1 to 6) or administered a single 200 mg dose of abrocitinib oral suspension alone (Formulations 1 to 6), after a fast of at least 10 hours before abrocitinib administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evidence or history of clinically significant dermatological condition (eg, atopic dermatitis or psoriasis) or visible rash present during physical examination.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Abrocitinib tablet
Drug: Abrocitinib Suspension F1
Drug: Famotidine
Drug: Abrocitinib Suspension F1
Drug: Abrocitinib Suspension F2
Drug: Abrocitinib Suspension F3
Drug: Abrocitinib Suspension F4
Drug: Abrocitinib Suspension F5
Drug: Abrocitinib Suspension F6
Drug: Abrocitinib Suspension F1 · Drug: Famotidine
Drug: Abrocitinib Suspension F2 · Drug: Famotidine
Drug: Abrocitinib Suspension F3 · Drug: Famotidine
Drug: Abrocitinib Suspension F4 · Drug: Famotidine
Drug: Abrocitinib Suspension F5 · Drug: Famotidine
Drug: Abrocitinib Suspension F6 · Drug: Famotidine
Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.
Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.
Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.
Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.
Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.
Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.
Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
AUCinf of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet
Area under the plasma concentration time profile from time 0 extrapolated to infinity (AUCinf) was measured. The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Cmax of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet
Maximum observed plasma concentration (Cmax) was measured. The adjusted mean differences and 90% CIs for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Assessment of Overall Liking After Administering Each Abrocitinib Oral Suspension Formulation (Formulation [F]1-F6) in Part B
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
Assessment of Mouth Feel After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
Assessment of Bitterness After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
Assessment of Tongue/Mouth Burn After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
Assessment of Salty Taste After Administering Each Abrocitinib Oral Suspension Formulation (F1-F6) in Part B
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
Assessment of Sour Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
Assessment of Sweet Taste After Administering Abrocitinib Oral Suspension Formulation (F1-F6) in Part B
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
Time frame: 0 Hours, 5, 10, 20 min after swallowing the suspension on Day 1 of each period.
AUCinf of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A
Area under the plasma concentration time profile from time 0 extrapolated to infinity.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
AUCinf of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A
Area under the plasma concentration time profile from time 0 extrapolated to infinity.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
AUCinf of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A
Area under the plasma concentration time profile from time 0 extrapolated to infinity.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Cmax of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A
Maximum observed plasma concentration.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Cmax of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A
Maximum observed plasma concentration.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Cmax of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A
Maximum observed plasma concentration.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose on Day 1 of each period.
Number of Participants With Treatment-Emergent Adverse Event
Adverse events (AEs): any untoward medical occurrence in a clinical investigation participant administered a product, without regard to relatedness. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Treatment-related TEAEs were any untoward medical occurrence attributed to study intervention. Relatedness to study intervention was determined by the investigator.
Time frame: Baseline up to follow-up (Day 36)
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
Participants with laboratory abnormalities (without regard to baseline abnormality) were reported.
Time frame: Baseline up to follow-up (Day 36)
Number of Participants With Clinically Significant Vital Sign Values
Participants with clinically significant vital sign values were reported.
Time frame: Baseline up to follow-up (Day 36)
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Values
Participants with clinically significant abnormal ECG values were reported.
Time frame: Baseline up to follow-up (Day 36)
Number of Participants With Nausea AEs
Number of participants who received abrocitinib 200 mg alone and who received abrocitinib 200 mg plus famotidine 40 mg and had nausea AEs were reported.
Time frame: Baseline up to follow-up (Day 36)
| Milestone | Treatment A-> B-> C-> D-> E-> F-> G-> H-> I | Treatment A-> C-> B-> L-> M-> N-> B-> J-> K | Treatment B-> A-> C-> K-> L-> M-> N-> B-> J | Treatment B-> C-> A-> I-> D-> E-> F-> G-> H | Treatment C-> A-> B-> H-> I-> D-> E-> F-> G | Treatment C-> B-> A-> J-> K-> L-> M-> N-> B |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 4 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 |
Area under the plasma concentration time profile from time 0 extrapolated to infinity (AUCinf) was measured. The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.
| nanogram*hour per milliliter (ng*hr/mL) | Abrocitinib 200 mg Commercial Tablet | Abrocitinib 200 mg Oral Suspension Formulation 1 | Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet |
|---|---|---|---|
| AUCinf of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet | 4623 ± 66 | 4601 ± 54 | 3096 ± 61 |
Maximum observed plasma concentration (Cmax) was measured. The adjusted mean differences and 90% CIs for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.
| nanogram per milliliter (ng/mL) | Abrocitinib 200 mg Commercial Tablet | Abrocitinib 200 mg Oral Suspension Formulation 1 | Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet |
|---|---|---|---|
| Cmax of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical Tablet | 1264 ± 67 | 1218 ± 56 | 189.1 ± 77 |
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
| Units on a scale | Abrocitinib 200 mg Oral Suspension Formulation 1 | Abrocitinib 200 mg Oral Suspension Formulation 2 | Abrocitinib 200 mg Oral Suspension Formulation 3 | Abrocitinib 200 mg Oral Suspension Formulation 4 | Abrocitinib 200 mg Oral Suspension Formulation 5 | Abrocitinib 200 mg Oral Suspension Formulation 6 |
|---|---|---|---|---|---|---|
| 0 Hours | 42.32 ± 35.117 | 72.10 ± 24.243 | 44.95 ± 34.422 | 42.19 ± 34.366 | 71.08 ± 27.491 | 69.29 ± 27.565 |
| 5 min | 40.21 ± 35.480 | 69.59 ± 25.882 | 42.83 ± 34.549 | 40.32 ± 32.691 | 71.87 ± 24.190 | 67.34 ± 27.632 |
| 10 min | 37.78 ± 34.025 | 65.65 ± 26.857 | 38.86 ± 30.808 | 33.90 ± 29.544 | 67.78 ± 24.919 | 62.89 ± 30.153 |
| 20 min | 35.55 ± 33.379 | 64.48 ± 27.644 | 37.56 ± 29.758 | 31.97 ± 29.563 | 61.68 ± 28.681 | 57.95 ± 28.483 |
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
| Units on a scale | Abrocitinib 200 mg Oral Suspension Formulation 1 | Abrocitinib 200 mg Oral Suspension Formulation 2 | Abrocitinib 200 mg Oral Suspension Formulation 3 | Abrocitinib 200 mg Oral Suspension Formulation 4 | Abrocitinib 200 mg Oral Suspension Formulation 5 | Abrocitinib 200 mg Oral Suspension Formulation 6 |
|---|---|---|---|---|---|---|
| 0 Hours | 40.12 ± 28.336 | 61.59 ± 26.218 | 40.79 ± 33.908 | 42.10 ± 30.178 | 63.59 ± 25.544 | 61.59 ± 31.543 |
| 5 min | 37.26 ± 27.903 | 54.22 ± 26.738 | 37.81 ± 33.045 | 38.67 ± 27.688 | 61.21 ± 25.335 | 60.48 ± 30.987 |
| 10 min | 35.61 ± 29.456 | 50.57 ± 26.578 | 35.18 ± 33.222 | 31.90 ± 24.808 | 55.33 ± 27.451 | 52.36 ± 31.626 |
| 20 min | 34.95 ± 30.347 | 42.22 ± 30.676 | 34.83 ± 33.221 | 26.89 ± 23.277 | 49.27 ± 29.356 | 44.33 ± 32.906 |
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
| Units on a scale | Abrocitinib 200 mg Oral Suspension Formulation 1 | Abrocitinib 200 mg Oral Suspension Formulation 2 | Abrocitinib 200 mg Oral Suspension Formulation 3 | Abrocitinib 200 mg Oral Suspension Formulation 4 | Abrocitinib 200 mg Oral Suspension Formulation 5 | Abrocitinib 200 mg Oral Suspension Formulation 6 |
|---|---|---|---|---|---|---|
| 0 Hours | 39.25 ± 30.773 | 64.25 ± 27.312 | 32.06 ± 27.383 | 28.63 ± 21.634 | 70.76 ± 27.869 | 63.28 ± 23.400 |
| 5 min | 36.54 ± 32.008 | 53.30 ± 30.392 | 31.14 ± 27.875 | 25.21 ± 19.685 | 63.62 ± 26.141 | 57.77 ± 28.066 |
| 10 min | 33.80 ± 31.609 | 47.72 ± 31.067 | 27.27 ± 25.124 | 20.95 ± 19.000 | 53.65 ± 25.657 | 49.41 ± 26.827 |
| 20 min | 30.83 ± 31.598 | 39.24 ± 31.325 | 24.92 ± 23.048 | 18.19 ± 19.554 | 45.56 ± 30.635 | 42.37 ± 27.755 |
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
| Units on a scale | Abrocitinib 200 mg Oral Suspension Formulation 1 | Abrocitinib 200 mg Oral Suspension Formulation 2 | Abrocitinib 200 mg Oral Suspension Formulation 3 | Abrocitinib 200 mg Oral Suspension Formulation 4 | Abrocitinib 200 mg Oral Suspension Formulation 5 | Abrocitinib 200 mg Oral Suspension Formulation 6 |
|---|---|---|---|---|---|---|
| 0 Hours | 28.90 ± 26.489 | 41.87 ± 30.238 | 25.87 ± 23.920 | 26.89 ± 25.884 | 35.75 ± 30.848 | 41.05 ± 32.462 |
| 5 min | 24.48 ± 25.226 | 35.40 ± 28.451 | 22.86 ± 22.477 | 22.67 ± 24.999 | 28.76 ± 25.809 | 37.89 ± 33.134 |
| 10 min | 23.73 ± 26.631 | 31.24 ± 26.305 | 18.29 ± 20.001 | 18.29 ± 22.999 | 22.82 ± 25.042 | 36.99 ± 32.737 |
| 20 min | 21.65 ± 28.937 | 23.97 ± 26.386 | 15.40 ± 20.156 | 16.51 ± 22.374 | 17.68 ± 21.927 | 33.68 ± 32.903 |
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
| Units on a scale | Abrocitinib 200 mg Oral Suspension Formulation 1 | Abrocitinib 200 mg Oral Suspension Formulation 2 | Abrocitinib 200 mg Oral Suspension Formulation 3 | Abrocitinib 200 mg Oral Suspension Formulation 4 | Abrocitinib 200 mg Oral Suspension Formulation 5 | Abrocitinib 200 mg Oral Suspension Formulation 6 |
|---|---|---|---|---|---|---|
| 0 Hours | 19.73 ± 26.872 | 39.52 ± 31.190 | 19.84 ± 21.560 | 21.84 ± 21.319 | 39.24 ± 30.962 | 34.98 ± 31.103 |
| 5 min | 19.34 ± 27.435 | 35.56 ± 28.372 | 13.78 ± 17.276 | 19.49 ± 22.504 | 33.43 ± 24.688 | 30.92 ± 30.413 |
| 10 min | 19.43 ± 27.776 | 29.49 ± 26.602 | 12.29 ± 17.121 | 15.94 ± 21.414 | 25.33 ± 22.853 | 31.85 ± 33.229 |
| 20 min | 19.61 ± 27.872 | 25.62 ± 26.613 | 12.35 ± 17.234 | 15.68 ± 21.290 | 20.89 ± 19.444 | 28.60 ± 28.337 |
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
| Units on a scale | Abrocitinib 200 mg Oral Suspension Formulation 1 | Abrocitinib 200 mg Oral Suspension Formulation 2 | Abrocitinib 200 mg Oral Suspension Formulation 3 | Abrocitinib 200 mg Oral Suspension Formulation 4 | Abrocitinib 200 mg Oral Suspension Formulation 5 | Abrocitinib 200 mg Oral Suspension Formulation 6 |
|---|---|---|---|---|---|---|
| 0 Hours | 25.44 ± 26.343 | 52.54 ± 27.703 | 24.86 ± 24.663 | 25.65 ± 22.452 | 48.35 ± 34.210 | 47.37 ± 33.103 |
| 5 min | 24.54 ± 26.919 | 46.32 ± 28.172 | 21.75 ± 23.849 | 21.71 ± 22.198 | 41.02 ± 31.652 | 39.73 ± 32.655 |
| 10 min | 23.16 ± 27.074 | 42.44 ± 29.892 | 18.70 ± 21.879 | 19.18 ± 20.652 | 33.30 ± 31.797 | 36.33 ± 32.522 |
| 20 min | 21.68 ± 27.373 | 37.05 ± 30.426 | 16.95 ± 21.472 | 18.16 ± 20.241 | 28.98 ± 31.338 | 34.31 ± 31.151 |
For the taste assessment in Part B of the study, the data used in the analysis was transcribed and rescaled to a score from 0 to 100 from the raw measurements on the Taste Assessment Questionnaire. The score of 0 was considered Favorable and the score of 100 was considered Not Favorable. Higher score means more unfavorable.
| Units on a scale | Abrocitinib 200 mg Oral Suspension Formulation 1 | Abrocitinib 200 mg Oral Suspension Formulation 2 | Abrocitinib 200 mg Oral Suspension Formulation 3 | Abrocitinib 200 mg Oral Suspension Formulation 4 | Abrocitinib 200 mg Oral Suspension Formulation 5 | Abrocitinib 200 mg Oral Suspension Formulation 6 |
|---|---|---|---|---|---|---|
| 0 Hours | 31.16 ± 26.157 | 82.16 ± 19.816 | 30.16 ± 29.536 | 27.90 ± 24.626 | 78.48 ± 28.017 | 74.53 ± 29.874 |
| 5 min | 38.02 ± 30.485 | 78.32 ± 23.269 | 33.14 ± 28.948 | 31.56 ± 29.205 | 76.60 ± 28.824 | 72.84 ± 29.862 |
| 10 min | 40.42 ± 32.265 | 78.35 ± 23.383 | 33.52 ± 29.713 | 32.38 ± 32.348 | 74.86 ± 29.812 | 64.81 ± 33.275 |
| 20 min | 44.54 ± 34.296 | 75.18 ± 26.743 | 35.46 ± 29.622 | 33.33 ± 31.472 | 73.46 ± 31.151 | 62.50 ± 33.720 |
Area under the plasma concentration time profile from time 0 extrapolated to infinity.
| ng*hr/mL | Abrocitinib 200 mg Commercial Tablet | Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet |
|---|---|---|
| AUCinf of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A | 1048 ± 34 | 903.2 ± 32 |
Area under the plasma concentration time profile from time 0 extrapolated to infinity.
| ng*hr/mL | Abrocitinib 200 mg Commercial Tablet | Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet |
|---|---|---|
| AUCinf of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A | 1369 ± 22 | 1108 ± 15 |
Area under the plasma concentration time profile from time 0 extrapolated to infinity.
| ng*hr/mL | Abrocitinib 200 mg Commercial Tablet | Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet |
|---|---|---|
| AUCinf of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A | 2139 ± 34 | 1705 ± 33 |
Maximum observed plasma concentration.
| ng/mL | Abrocitinib 200 mg Commercial Tablet | Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet |
|---|---|---|
| Cmax of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A | 216.8 ± 82 | 57.38 ± 55 |
Maximum observed plasma concentration.
| ng/mL | Abrocitinib 200 mg Commercial Tablet | Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet |
|---|---|---|
| Cmax of Abrocitinib Metabolite (PF-07055087/M2) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A | 214.3 ± 58 | 56.42 ± 42 |
Maximum observed plasma concentration.
| ng/mL | Abrocitinib 200 mg Commercial Tablet | Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet |
|---|---|---|
| Cmax of Abrocitinib Metabolite (PF-07054874/M4) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A | 400.5 ± 39 | 87.96 ± 47 |
Adverse events (AEs): any untoward medical occurrence in a clinical investigation participant administered a product, without regard to relatedness. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Treatment-related TEAEs were any untoward medical occurrence attributed to study intervention. Relatedness to study intervention was determined by the investigator.
| Participants | Abrocitinib 200 mg Commercial Tablet | Abrocitinib 200 mg Oral Suspension Formulation 1 | Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet | Abrocitinib 200 mg Oral Suspension Formulation 1-6 | Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-6 |
|---|---|---|---|---|---|
| All-causality AEs | 6 | 8 | 6 | 5 | 2 |
| Treatment-related AEs | 3 | 5 | 0 | 4 | 0 |
| SAEs | 0 | 0 | 0 | 0 | 0 |
Participants with laboratory abnormalities (without regard to baseline abnormality) were reported.
| Participants | Abrocitinib 200 mg Commercial Tablet | Abrocitinib 200 mg Oral Suspension Formulation 1 | Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet | Abrocitinib 200 mg Oral Suspension Formulation 1-6 | Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-6 |
|---|---|---|---|---|---|
| Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | 0 | 0 | 0 | 0 | 0 |
Participants with clinically significant vital sign values were reported.
| Participants | Abrocitinib 200 mg Commercial Tablet | Abrocitinib 200 mg Oral Suspension Formulation 1 | Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet | Abrocitinib 200 mg Oral Suspension Formulation 1-6 | Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-6 |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Vital Sign Values | 0 | 0 | 0 | 0 | 0 |
Participants with clinically significant abnormal ECG values were reported.
| Participants | Abrocitinib 200 mg Commercial Tablet | Abrocitinib 200 mg Oral Suspension Formulation 1 | Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet | Abrocitinib 200 mg Oral Suspension Formulation 1-6 | Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-6 |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Values | 0 | 0 | 0 | 0 | 0 |
Number of participants who received abrocitinib 200 mg alone and who received abrocitinib 200 mg plus famotidine 40 mg and had nausea AEs were reported.
| Participants | Abrocitinib 200 mg Alone | Abrocitinib 200 mg Plus Famotidine 40 mg |
|---|---|---|
| Number of Participants With Nausea AEs | 12 | 0 |
Collected over Baseline up to follow-up (Day 36). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abrocitinib 200 mg Commercial Tablet | 0/18 (0%) | 0/18 (0%) | 6/18 (33.3%) |
| Abrocitinib 200 mg Oral Suspension Formulation 1 | 0/18 (0%) | 0/18 (0%) | 8/18 (44.4%) |
| Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet | 0/18 (0%) | 0/18 (0%) | 6/18 (33.3%) |
| Aborcitinib 200 mg Oral Suspension Formulation 1-6 | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-6 | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Event | Abrocitinib 200 mg Commercial Tablet | Abrocitinib 200 mg Oral Suspension Formulation 1 | Famotidine 40 mg Tablet + Abrocitinib 200 mg Commercial Tablet | Aborcitinib 200 mg Oral Suspension Formulation 1-6 | Famotidine 40 mg Tablet + Abrocitinib 200 mg Oral Suspension Formulation 1-6 |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/18 | 5/18 | 0/18 | 4/9 | 0/10 |
| HungerGeneral disorders | 1/18 | 0/18 | 0/18 | 2/9 | 0/10 |
| Incision site complicationInjury, poisoning and procedural complications | 2/18 | 2/18 | 4/18 | 0/9 | 0/10 |
| HeadacheNervous system disorders | 2/18 | 3/18 | 0/18 | 1/9 | 0/10 |
| Feeling abnormalGeneral disorders | 0/18 | 1/18 | 0/18 | 1/9 | 0/10 |
| Vessel puncture site painGeneral disorders | 0/18 | 0/18 | 1/18 | 1/9 | 0/10 |
| AcneSkin and subcutaneous tissue disorders | 0/18 | 0/18 | 0/18 | 1/9 | 0/10 |
| Abdominal pain upperGastrointestinal disorders | 0/18 | 0/18 | 0/18 | 0/9 | 1/10 |
| ContusionInjury, poisoning and procedural complications | 0/18 | 0/18 | 0/18 | 0/9 | 1/10 |
| Tension headacheNervous system disorders | 0/18 | 0/18 | 0/18 | 0/9 | 1/10 |
This was a phase 1, randomized, crossover designed relative bioavailability (rBA) study conducted in healthy adult participants, including 2 parts to investigate the rBA (part A), and taste and palatability (part B) of different formulations. Participants were all healthy adults and were randomized into the study, and may or may not participate both parts of the study. Thus baseline characteristics of participants were combined.
| Age, Continuous(Years) | Treatment A-> B-> C-> D-> E-> F-> G-> H-> I | Treatment A-> C-> B-> L-> M-> N-> B-> J-> K | Treatment B-> A-> C-> K-> L-> M-> N-> B-> J | Treatment B-> C-> A-> I-> D-> E-> F-> G-> H | Treatment C-> A-> B-> H-> I-> D-> E-> F-> G | Treatment C-> B-> A-> J-> K-> L-> M-> N-> B | Total |
|---|---|---|---|---|---|---|---|
| Mean | 34.3 ± 18.01 | 34.3 ± 7.51 | 42.3 ± 7.02 | 42.0 ± 6.32 | 34.7 ± 5.86 | 43.3 ± 8.50 | 38.7 ± 9.14 |
| Sex: Female, Male(Participants) | Treatment A-> B-> C-> D-> E-> F-> G-> H-> I | Treatment A-> C-> B-> L-> M-> N-> B-> J-> K | Treatment B-> A-> C-> K-> L-> M-> N-> B-> J | Treatment B-> C-> A-> I-> D-> E-> F-> G-> H | Treatment C-> A-> B-> H-> I-> D-> E-> F-> G | Treatment C-> B-> A-> J-> K-> L-> M-> N-> B | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 1 | 2 | 0 | 2 | 5 |
| Male | 3 | 3 | 2 | 2 | 3 | 1 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Treatment A-> B-> C-> D-> E-> F-> G-> H-> I | Treatment A-> C-> B-> L-> M-> N-> B-> J-> K | Treatment B-> A-> C-> K-> L-> M-> N-> B-> J | Treatment B-> C-> A-> I-> D-> E-> F-> G-> H | Treatment C-> A-> B-> H-> I-> D-> E-> F-> G | Treatment C-> B-> A-> J-> K-> L-> M-> N-> B | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 0 | 0 | 1 | 1 | 6 |
| Not Hispanic or Latino | 2 | 0 | 3 | 4 | 2 | 2 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment A-> B-> C-> D-> E-> F-> G-> H-> I | Treatment A-> C-> B-> L-> M-> N-> B-> J-> K | Treatment B-> A-> C-> K-> L-> M-> N-> B-> J | Treatment B-> C-> A-> I-> D-> E-> F-> G-> H | Treatment C-> A-> B-> H-> I-> D-> E-> F-> G | Treatment C-> B-> A-> J-> K-> L-> M-> N-> B | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 | 2 | 1 | 1 | 8 |
| White | 2 | 1 | 0 | 2 | 2 | 2 | 9 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jun 2021 to primary completion in Oct 2021, 4 months.
Results were first posted in Nov 2024, 3 years after primary completion.
Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 4 months is below that.
Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrocitinib